Dr Ajeet Singh

CNSDose is a pharmacogenomics company founded by psychiatrist Professor Ajeet Singh that specializes in genetically guided prescribing for mental health conditions. The company developed a proprietary algorithm and genetic test designed to help clinicians select the most effective antidepressants and optimal dosages for patients based on their unique genetic profiles. By analyzing genes involved in drug metabolism and transport, such as the CYP450 family and the ABCB1 transporter, CNSDose aims to reduce the trial-and-error process often associated with psychiatric medication, thereby improving patient outcomes and reducing adverse reactions. In 2022, the company was acquired by Australian Clinical Labs (ACL), a major Australian diagnostics firm, to integrate its specialized pharmacogenomic testing into broader clinical pathology services.